| 3.13 Data as of 10:06am ET |  -0.0199 / -0.63%Today’s Change | 2.47 Today|||52-Week Range 4.59 | -7.39% Year-to-Date |
| Previous close | 3.15 |
| Today’s open | 3.13 |
| Day’s range | 3.13 - 3.14 |
| Volume | 2,370 |
| Average volume (3 months) | 157,110 |
| Market cap | $97.9M |
| Dividend yield | -- |
| Earnings growth (last year) | -56.96% |
| Earnings growth (this year) | +54.03% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| TROVTrovagene Inc | -0.08 | -1.18% |
| LPDXLipoScience Inc | +0.17 | +2.91% |
| TTHITransition Therapeut... | -0.04 | -1.33% |
| GALTGalectin Therapeutic... | -0.03 | -0.68% |
| Last reporting date | May 14, 2013 |
| EPS forecast (this quarter) | -$0.68 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$37.8M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Director Armando Anido, MBA |
President Terri B. Sebree |
Corporate headquarters Conshohocken, Pennsylvania |
.
